Shanghai, China, June 2, 2026 — Henlius (2696.HK), a subsidiary of Fosun Pharma, announced that data from ASTRUM-006, a Phase 3 clinical study of its self-developed novel anti–PD-1 monoclonal antibody HANSIZHUANG(serplulimab, trade name in Europe: Hetronifly^®)

The 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be grandly held from May 29 to June 2 in Chicago, United States. As the most influential academic event in the global oncology field, this year's ASCO will bring together top oncology experts from around the world and the latest clinical research findings.

The updated data of efficacy and safety of Luvometinib (FCN-159), a self-developed innovative drug by Fosun Pharma, in pediatric participants with neurofibromatosis type 1 from a phase 2 study was presented in the American Society of Clinical Oncology (ASCO) Annual Meeting on May 22, 2025

Recently, experts have settled in the Academician Workstation of Fosun Pharma, including Professor Jiang Zhihong, Vice President of Macau University of Science and Technology. Professor Jiang Zhihong is an internationally renowned natural pharmaceutical chemist, studying fields such as natural pharmaceutical chemistry, metabolomics, quality standard of traditional Chinese medicine (TCM) and bioorganic chemistry.

On November 6, 2021, as a parallel supporting event of the 4th China International Import Expo (CIIE), the 4th Hongqiao International Health Technology Innovation Forum with the theme of "Innovation for Good Health" was successfully held. This forum was sponsored by the International Health Exchange and Cooperation Center NHC PRC (IHECC) and China Pharmaceutical Innovation and Research Development Association, undertaken by Shanghai Biopharmaceutics Industry Association, Fosun International Limited and Fosun Pharma, and supported by Shanghai Municipal Health Commission, Shanghai Municipal Commission of Economy and Informatization, Science and Technology Commission of Shanghai Municipality and Shanghai Municipal Medical Products Administration.

Chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. Aiming to be a healthcare group with a global presence, Fosun Pharma, established in Shanghai in 1994, has built its core business around innovative drug R&D and manufacturing.

In this meeting, Henlius releases phase 2 study results of serplulimab (HLX10, novel anti-PD-1 antibody), in patients with advanced cervical cancer in an oral presentation.

In this meeting, Henlius releases phase 3 study results of HLX04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.